Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091866 · ClinicalTrials.gov registry record · Early Phase 1
Natural Progesterone for the Treatment of Recurrent Glioblastoma
A Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma, sponsored by Emory University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05091866 is a Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 4 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05091866, a Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Therapeutic Progesterone
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05091866
The ClinicalTrials.gov registry entry for NCT05091866 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (94% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05091866 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT05091866 about?
NCT05091866 is a clinical study titled "Natural Progesterone for the Treatment of Recurrent Glioblastoma". This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progester...
What is the current status of trial NCT05091866?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2022-04-11. Estimated completion is 2027-04-01.
What conditions does trial NCT05091866 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT05091866?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Therapeutic Progesterone (BIOLOGICAL).
Who is sponsoring clinical trial NCT05091866?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091866 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
-
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Fimepinostat in Treating Brain Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Early Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.